Related Experiment Videos
[Nitrogen oxide inhalation in critically ill patients].
J Bonde1, K Antonsen, S W Henneberg
1Anaestesiologisk afdeling, Amtssygehuset i Herlev.
Ugeskrift for Laeger
|February 19, 2000
Summary
Inhaled nitric oxide (iNO) improves oxygenation and reduces pulmonary hypertension but does not decrease mortality in severe respiratory failure. In neonates, iNO may reduce the need for extracorporeal membrane oxygenation.
Area of Science:
- Critical care medicine
- Pulmonology
- Neonatology
Context:
- Inhaled nitric oxide (iNO) is a widely adopted therapy for severe hypoxemic respiratory failure and pulmonary hypertension.
- Clinical evidence consistently shows iNO improves oxygenation and lowers pulmonary artery pressures.
Purpose:
- To evaluate the efficacy of iNO in reducing mortality in patients with severe respiratory failure.
- To assess the impact of iNO on the need for extracorporeal membrane oxygenation (ECMO) in neonates.
Summary:
- Randomized trials have not demonstrated a mortality benefit of iNO in adult patients with severe respiratory failure.
- iNO can decrease the requirement for ECMO in neonates suffering from severe respiratory failure and pulmonary hypertension.
- Non-pharmacological interventions like optimizing ventilator settings and prone positioning should be considered before initiating iNO in adults.
Impact:
- Highlights the nuanced role of iNO, emphasizing its benefits in specific populations (neonates) and clinical outcomes (oxygenation, ECMO reduction) while questioning its mortality benefit in adults.
- Suggests a stepwise approach to managing severe respiratory failure, prioritizing conventional therapies before considering iNO for adult patients.
- Informs clinical decision-making regarding the use of inhaled nitric oxide in critical care settings.